Display Settings:

Format

Send to:

Choose Destination
Nat Rev Cancer. 2009 Dec;9(12):874-85. doi: 10.1038/nrc2761.

Mucins in cancer: function, prognosis and therapy.

Author information

  • Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts 02115, USA. Donald_Kufe@dfci.harvard.edu

Abstract

Epithelia are protected from adverse conditions by a mucous barrier. The secreted and transmembrane mucins that constitute the mucous barrier are largely unrecognized as effectors of carcinogenesis. However, both types of mucins are intimately involved in inflammation and cancer. Moreover, diverse human malignancies overexpress transmembrane mucins to exploit their role in signalling cell growth and survival. Mucins have thus been identified as markers of adverse prognosis and as attractive therapeutic targets. Notably, the findings that certain transmembrane mucins induce transformation and promote tumour progression have provided the experimental basis for demonstrating that inhibitors of their function are effective as anti-tumour agents in preclinical models.

PMID:
19935676
[PubMed - indexed for MEDLINE]
PMCID:
PMC2951677
Free PMC Article

Images from this publication.See all images (5)Free text

Figure 1
Figure 2
Figure 3
Figure 4
Figure 5
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Nature Publishing Group Icon for PubMed Central
    Loading ...
    Write to the Help Desk